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Chronic kidney disease (CKD) and end-stage renal disease
(ESRD) are emerging public health problems in developing
countries, and need changes in health-care policy. ESRD
incidence data are not available from large parts of the
developing world including South Asia. We report the
ESRD incidence in a large urban population in India. ESRD
incidence was estimated for four consecutive calendar
years (2002–2005) among 572 029 subjects residing in
36 of the 56 wards of the city of Bhopal. These subjects are
beneficiaries of free health care in a hospital established
after the 1984 Union Carbide Industrial Accident. Crude
and age-adjusted incidence rates were calculated. A total of
346 new ESRD patients were diagnosed during the study
period; 86 in 2002, 82 in 2003, 85 in 2004, and 93 in 2005.
Average crude and age-adjusted incidence rates were 151
and 232 per million population, respectively. The mean age
was 47 years, and 58% were males. Diabetic nephropathy
was the commonest (44%) cause of ESRD. This study provides
the first population-based ESRD incidence data from India
and reveals it to be higher than previously estimated.
Diabetic nephropathy is the leading cause of ESRD. Changes
are required in health-care policy for optimal care
of CKD patients and efficient resource utilization for
management of those with ESRD.
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Chronic kidney disease (CKD) and end-stage renal disease
(ESRD) have become worldwide public health problems.
These conditions increase patient morbidity and mortality
risks and put major economic strain on the health-care
systems. In US alone, over 30 million people have been
diagnosed to have CKD and it is estimated that over 600 000
will need renal replacement therapy by 2010, costing USD 28
billion.1 The population of India exceeds one billion and is
projected to become the major reservoir of chronic diseases
like diabetes and hypertension.2 With 25–40% of these
subjects likely to develop CKD, the ESRD burden will rise,
and the health-care system would need to take care of these
individuals. However, in the absence of any registry, data on
incidence of ESRD in India or other countries of South Asia
do not exist. A figure of 100 per million population (pmp)
per year is often cited, based on estimates from rest of the
world, tertiary care center data, and collective experience of
experienced nephrologists.3–5
Further, it has been estimated that less than 10% of all
Indian ESRD patients receive any meaningful renal replace-
ment therapy (RRT).3–5 As the RRT delivery infrastructure
improves, it is imperative that the ESRD incidence for our
country be known definitively to plan care for these
individuals. This study provides the first estimate of ESRD
incidence in a large population base, determines the
contribution of diabetes to ESRD, and provides a basis for
health-care policy planning.
RESULTS
A total of 346 new patients were diagnosed to have ESRD
during the study period. The average annual crude and age-
adjusted incidence rates for the period were 151 and
229 pmp, respectively. Table 1 gives the number of new
ESRD cases, crude and age-adjusted incidence rates, gender
distribution, and proportion of subjects with one of diabetic
nephropathy for each year. The laboratory parameters at the
time of diagnosis are shown in Table 2. Figure 1 shows the
overall and age-specific incidence rates over the 4 years.
The initial dialysis modality was hemodialysis for all
subjects. A total of five patients shifted to continuous
ambulatory peritoneal dialysis, and 21 underwent living
donor transplant. A total of seven patients elected not to start
any RRT and withdrew from active treatment.
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DISCUSSION
This study presents the first population-based ESRD
incidence figure from India, the second most populous
country in the world, and reveals the previous guesses about
the ESRD incidence (approximately 100 pmp) to be gross
underestimates. This rate is also higher than the age-adjusted
ESRD incidence of 115–123 pmp determined in the 1980s
among Indo-Asian immigrants in UK.6 Higgins et al.7 in
1995 reported overall dialysis take-on rates of 248–497 pmp
in Asian/Afro-Caribbean population in the city of Coventry,
UK. In both studies, the incidence was 4–5 times higher than
that observed in the white population residing in the same
areas. We also show that the mean age of patients entering
ESRD is lower than that reported in the west.
ESRD incidence is rising worldwide, and developing world
is no exception. The economic growth and urbanization has
been accompanied by increase in the prevalence of non-
communicable diseases like diabetes, hypertension, and
atherovascular diseases. The total burden of ESRD faced by
the nation remains unknown owing to lack of access to health
care, organized chronic disease management programs, and
national registries. Thus, the data in this study are of great
value for national healthcare policy planning. Assuming the
incidence to be uniform in all parts of the country, it can be
estimated that approximately 152 000 new ESRD patients
require RRT every year in India. The resources and skill for
taking care of this large case-load, both in terms of personnel
and health-care infrastructure, do not exist currently3–5,8,9
and would need to be created.
Unlike at the BMHRC, the high treatment cost limits
access to RRT for most Indians.3 It is estimated that 490%
of ESRD patients cannot afford long-term RRT and die
within weeks to months of diagnosis.3,8 With the incidence of
diabetes and hypertension projected to rise further, ESRD
incidence rate is likely to climb, and facilities need to be
developed to take care of the increasing number of existing
and incident ESRD cases.
Some data are available on the pattern of causes of ESRD
in India. Glomerulonephritides (presumably infection-
related), interstitial nephritis (thought to be due to potential
environmental exposures to nephrotoxins), and stones have
been reported to be the most frequent causes.9–11 This study
highlights the emergence of diabetic nephropathy as the
major cause of ESRD in India. This finding is consistent with
the worldwide trend of steady rise in the contribution of
diabetes to ESRD. In a recent population-based survey,
diabetes was the cause of CKD in 41% cases.12 Another
study13 involving several hospitals in India found that 29% of
CKD subjects had diabetic nephropathy. Variation can be
encountered in prevalence of diabetes depending upon the
rural/urban divide, level of economic development, and
Table 1 | Number of new cases of ESRD and the incidence data
2002 2003 2004 2005
New ESRD cases 86 82 85 93
Incidence (pmp) 150 143 149 163
Age-adjusted incidence (pmp) 232 186 317 181
Sex ratio (M:F) 55/45 63/37 65/35 52/48
Age (years) 46715 50710 47713 46712
Diabetic nephropathy (%) 47 43 40 46
ESRD, end-stage renal disease; F, female; M, male; pmp, per million population.
Table 2 | Subject characteristics at the start of dialysis
2002 2003 2004 2005
Percentage of cases with
Systolic BP4140 mmHg 86 51 65 61
Diastolic BP490 mmHg 72 54 61 58
Hemoglobin (g/dl) 8.271.7 8.072.0 8.672.1 9.171.7
Blood urea (mg/dl) 228793 2267102 197779 1917107
Serum creatinine (mg/dl) 9.873.5 9.774.5 8.773.9 9.274.1
CG GFRa (ml/min) 7.774.3 8.473.6 7.973.5 8.173.7
MDRD GFRb (ml/min/1.73 m2 BSA) 6.774.7 6.973.5 7.272.9 6.973.1
BP, blood pressure; BSA, body surface area; CG, chronic glomerulonephritis; GFR, glomerular filtration rate; MDRD, modification of diet in renal disease.
aGlomerular filtration rate calculated by Cockroft–Gault formula.
bGlomerular filtration rate calculated by the modified MDRD equation.
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Figure 1 | Overall and age-specific ESRD incidence rates during
the study period.
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genetic background of the population studied. As diabetes is
the main cause of ESRD, wide variations could influence
ESRD incidence. The exact cause remained unknown in a
majority of non-diabetics in this study, probably because of
the delayed presentation. The UK study on Indo-Asians with
ESRD6 showed a seven-fold higher incidence of diabetic renal
disease compared to whites and a high frequency of patients
with advanced kidney failure of unknown etiology and small
smooth kidneys.
The ideal method to determine the incidence of a disease
is to constitute a healthy representative cohort and follow it
up for many years. This study utilized a large population
segment in a defined geographic area. Referral bias and
population migration may introduce errors, ESRD is not
asymptomatic and the care is expensive, making it unlikely
that any patient would not have reported to the only hospital
in the region that provides free treatment. The large
population size and inclusion of subjects irrespective of
socioeconomic, educational, or religious status compensates
for any limitations. As this population was identified for
dispensation of benefits arising out of the compensation of
the 1984 Union Carbide methyl isocyanate gas tragedy, it may
be argued that methyl isocyanate exposure could have
confounded the results. However, extensive studies have not
documented any nephrotoxic effect, pulmonary fibrosis being
the only proven long-term consequence of methyl isocyanate
exposure.14,15 The year-to-year consistency in the incidence
rates, demographics, and laboratory profile also lend
credibility to the data. The mean age of subjects in this
study is close to the reported figure of patients entering ESRD
programs in the subcontinent. Finally, India is a diverse
country with a heterogeneous population mix in terms of
ethnicities, rural-urban divide, and level of economic
development. Although BMHRC is situated in an urban
location, the population it serves is heterogeneous, represent-
ing all socioeconomic strata living in urban as well as rural
areas. Still, finding of a single study coming from a defined
geographic area should be generalized to the whole popula-
tion with appropriate caution.
In summary, this population-based study has for the first
time provided an estimate of ESRD incidence in India. The
crude and age-adjusted incidence rates of 151 and 232 pmp
are significantly higher than the estimates projected so far.
Increased efforts are required by the health-care policy-
makers to ensure availability and optimum utilization of
resources for ESRD care.
MATERIALS AND METHODS
The study was conducted at Bhopal Memorial Hospital and
Research Centre (BMHRC), a multi-specialty tertiary care hospital
located in the city of Bhopal in Madhya Pradesh, a province in
central India. BMHRC was set up in the year 2000 on the direction
of the Supreme Court of India to provide health care to a defined
population presumed to be potentially affected by the Union
Carbide Gas Tragedy of 1984. Every individual residing in 36 of the
56 wards of the city was given a unique identifier document, and
became entitled to free medical care through BMHRC and its eight
out-reach centers located in the community. The total number of
registered beneficiaries is 572 029.
All CKD patients from within this population present either
through the out-reach centers or directly to BMHRC. The unique
identifier number allotted to each subject prevents any duplication
of records or redundancy of referrals. Availability of free health care
(including dialysis) ensures presentation of all ESRD patients to
BMHRC.
The incidence of new ESRD patients in this defined population
was estimated for four consecutive calendar years, that is,
2002–2005. Patients were classified as having ESRD as per the
following case definitions: (i) patients starting regular dialysis, (ii)
patients those who were advised regular dialysis but decided to
withdraw, and (iii) patients who received a renal transplant. Patients
dialyzed for acute renal failure, or those CKD patients in whom the
renal function improved or recovered (acute-on-chronic renal
failure) were excluded. Incidence was expressed as number pmp
per year. Age-adjusted incidence rates were calculated using the 2001
population census data.
Basic demographic and clinical profile at the time of dialysis
initiation was recorded for all subjects. Glomerular filtration rate at
the start of dialysis was estimated by Cockcroft–Gault’s formula and
by the modified Modification of Diet in Renal Disease equation.
Diabetic nephropathy was defined as ESRD in the presence of
diabetes, normal-sized kidneys on ultrasonography, and diabetic
retinopathy.
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